CanBas plans to allot three types of stock acquisition rights by third-party allotment to SBI Securities, aiming to raise approximately 418 million yen in total. The total number of shares potentially issuable is 4,800,000 shares. The 22nd Series includes an exercise price adjustment clause, while the 23rd and 24th Series include an option to apply adjustments. Detailed provisions disclose planned sales by the allottees and rigorous regulatory compliance measures. Proceeds will be used for costs including the CBP501 Phase 3 clinical trial. The term is from 2026\/11\/2 to 2028\/11\/2, and conditions such as collateral, interest rates and maximum lending are presented.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4575","jir_company_name":"CanBas Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4575-20261014-01.pdf","jir_short_summary":"CanBas plans to allot three types of stock acquisition rights by third-party allotment to SBI Securities, aiming to raise approximately 418 million yen in total. The total number of shares potentially issuable is 4,800,000 shares. The 22nd Series includes an exercise price adjustment clause, while the 23rd and 24th Series include an option to apply adjustments. Detailed provisions disclose planned sales by the allottees and rigorous regulatory compliance measures. Proceeds will be used for costs including the CBP501 Phase 3 clinical trial. The term is from 2026\/11\/2 to 2028\/11\/2, and conditions such as collateral, interest rates and maximum lending are presented.","jir_summary":"### Overview of Capital Policy\nCanBas adopts a scheme to simultaneously issue stock acquisition rights by third-party allotment in three tranches, creating rights that can be converted into a total of 4,800,000 ordinary shares in the future. The 22nd Series includes an exercise price adjustment clause allowing the price to be adjusted according to share price movements, while the 23rd and 24th Series are designed to be adjusted depending on resolution to exercise the adjustment option. The allottee is SBI Securities, and the proceeds are scheduled to be applied to clinical trial costs and related expenses.\n\n### Outlook and Risks\nThe primary objective of the fundraising is to secure costs for the Phase 3 clinical trial. Current cash on hand is limited. Share dilution is expected to be approximately 24% in total; however, mechanisms such as exercise requests and suspension designations may suppress dilution to some extent. Depending on future funding needs, additional fundraising measures may be considered. Note that sales by the allottees depending on milestones could affect the share price.","jir_financial_highlights":"Amount of funds to be raised (estimated net proceeds): 4,175,640,000 yen (Fundraising via stock acquisition rights)\nSubscription payment amount for these stock acquisition rights: 15,140,000 yen (Initial subscription payment)\nTotal number of issued stock acquisition rights: 4,800,000 shares (Total)","jir_category":"","jir_hashtags":"#CanBas, #CapitalPolicy, #StockAcquisitionRights, #ThirdPartyAllotment","jir_key_figures":"4,800,000 shares: Total number of these stock acquisition rights\n4,175,640,000 yen: Estimated net proceeds\n42,000 million yen: Total intended use of these stock acquisition rights (breakdown of uses)","jir_meta_title":"CanBas Co., Ltd. \u2014 Notice of Issuance of Stock Acquisition Rights by Third-Party Allotment | October 2026","jir_meta_description":"CanBas will allot stock acquisition rights to SBI Securities via third-party allotment. The 22nd Series includes an exercise price adjustment clause; the 23rd and 24th Series include an option to apply adjustments. Proceeds will be used for CBP501 clinical trial costs and related expenses. Term: November 2, 2026 to November 2, 2028.","jir_og_title":"CanBas to Raise Funds via Issuance of Stock Acquisition Rights | October 2026","jir_og_description":"CanBas will allot stock acquisition rights to SBI Securities to fund clinical trial costs and related expenses. The 22nd Series features share price-linked adjustment; the 23rd and 24th Series are optional adjustment types.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58229,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-130828","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n